Literature DB >> 11517933

Immunochemical localisation of cathepsin S, cathepsin L and MHC class II-associated p41 isoform of invariant chain in human lymph node tissue.

V Zavasnik-Bergant1, A Sekirnik, R Golouh, V Turk, J Kos.   

Abstract

Antigen presentation by MHC class II molecules requires cysteine proteases (CP) for two convergent proteolytic processes: stepwise degradation of the invariant chain (Ii) and generation of immunogenic peptides. Their activity is controlled by intracellular CP inhibitors, including presumably the p41 isoform of invariant chain (p41 Ii), which is in vitro a potent inhibitor of cathepsin L but not of cathepsin S. In order to evaluate the inhibitory potential of p41 Ii in antigen-presenting cells (APC), these three proteins were stained in lymph node tissue using specific monoclonal and polyclonal antibodies. The most abundant labelling was observed in subcapsular (cortical) and trabecular sinuses of the lymph node. In this area the most frequent APC were macrophages, as confirmed by the CD68 cell marker. Using confocal fluorescence microscopy, co-localisation of p41 Ii with cathepsin S, but not with cathepsin L was found in these cells. Our results are consistent with the hypothesis that cathepsin S participates in degradation of the invariant chain, but they do not support the association between cathepsin L and p41 Ii in APC.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11517933     DOI: 10.1515/BC.2001.096

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  8 in total

1.  Inhibitory p41 isoform of invariant chain and its potential target enzymes cathepsins L and H in distinct populations of macrophages in human lymph nodes.

Authors:  Valentina Zavasnik-Bergant; Ana Schweiger; Tadeja Bevec; Rastko Golouh; Vito Turk; Janko Kos
Journal:  Immunology       Date:  2004-07       Impact factor: 7.397

2.  Cathepsin S in tumours, regional lymph nodes and sera of patients with lung cancer: relation to prognosis.

Authors:  J Kos; A Sekirnik; G Kopitar; N Cimerman; K Kayser; A Stremmer; W Fiehn; B Werle
Journal:  Br J Cancer       Date:  2001-10-19       Impact factor: 7.640

Review 3.  Cysteine cathepsins as regulators of the cytotoxicity of NK and T cells.

Authors:  Milica Perišić Nanut; Jerica Sabotič; Anahid Jewett; Janko Kos
Journal:  Front Immunol       Date:  2014-12-02       Impact factor: 7.561

4.  Role of Cathepsin S in Periodontal Inflammation and Infection.

Authors:  S Memmert; A Damanaki; A V B Nogueira; S Eick; M Nokhbehsaim; A K Papadopoulou; A Till; B Rath; S Jepsen; W Götz; C Piperi; E K Basdra; J A Cirelli; A Jäger; J Deschner
Journal:  Mediators Inflamm       Date:  2017-12-06       Impact factor: 4.711

5.  Role of cathepsin S In periodontal wound healing-an in vitro study on human PDL cells.

Authors:  Svenja Memmert; Marjan Nokhbehsaim; Anna Damanaki; Andressa V B Nogueira; Alexandra K Papadopoulou; Christina Piperi; Efthimia K Basdra; Birgit Rath-Deschner; Werner Götz; Joni A Cirelli; Andreas Jäger; James Deschner
Journal:  BMC Oral Health       Date:  2018-04-05       Impact factor: 2.757

6.  A highly significant association between Cathepsin S gene polymorphisms rs12068264 and chronic obstructive pulmonary disease susceptibility in Han Chinese population.

Authors:  Sheng-Lan Gao; Ya-Hong Wang; Chun-Yan Li; La-Wei Yang; Bao-An Zou; Zu-Guang Chen; Wei-Min Yao; Ze-Qing Song; Jun-Fen Cheng; Zi-Ying Lin; Gang Liu
Journal:  Biosci Rep       Date:  2018-07-18       Impact factor: 3.840

Review 7.  Involvement of Cathepsins in Innate and Adaptive Immune Responses in Periodontitis.

Authors:  Xu Yan; Zhou Wu; Biyao Wang; Tianhao Yu; Yue Hu; Sijian Wang; Chunfu Deng; Baohong Zhao; Hiroshi Nakanishi; Xinwen Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2020-03-31       Impact factor: 2.629

Review 8.  Single-cell RNA sequencing combined with whole exome sequencing reveals the landscape of the immune pathogenic response to chronic mucocutaneous candidiasis with STAT1 GOF mutation.

Authors:  Xiaodi Lu; Keming Zhang; Weiwei Jiang; Hang Li; Yue Huang; Mingwei Du; Jian Wan; Yanyun Cao; Lin Du; Xiaogang Liu; Weihua Pan
Journal:  Front Immunol       Date:  2022-09-15       Impact factor: 8.786

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.